Our evaluation and opinions of the EPI-321 clinical trial design and potential based on the pre-clinical data
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Our evaluation and opinions of the EPI-321 clinical trial design and potential based on the pre-clinical data
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
"But did you bleed him? - Aesculapius says that bleeding is not a cure. It is only a way of proving that you are a physician at the expense of your patient." Finally, we discuss the EPI-321 epigenetic editing phase I/II clinical trial design and its potential for answering key questions necessary for going to phase III and for providing benefit to participants and patients.
Pas encore de commentaire